Status:
COMPLETED
Computed Tomography (CT) - Guided Brachytherapy Versus Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma
Lead Sponsor:
University of Magdeburg
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Percutaneous, image-guided tumor ablation has evolved as a genuine alternative for the treatment of unresectable hepatocellular carcinoma. Published data exploring stereotactic or proton beam percutan...
Eligibility Criteria
Inclusion
- diagnosis of HCC by histopathology or according to the criteria of the Consensus Conference of the European Association for the Study of Liver Disease
- unresectable HCC
- Karnofsky-Index \> 70
- estimated life expectancy \> 16 weeks
- adequate bone marrow function
- adequate contraception for female patients
- informed consent
Exclusion
- portal vein thrombosis on the tumor side
- extrahepatic spread
- Child C
- other untreated malignant disease
- general contraindication for chemotherapy
- active infectious disease
- neuropathy, platin-allergy
- pregnancy
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
77 Patients enrolled
Trial Details
Trial ID
NCT00807300
Start Date
October 1 2006
End Date
December 1 2015
Last Update
December 3 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinic of Diagnostic Radiology and Nuclear Medicine, Medical Faculty, University Magdeburg
Magdeburg, Saxony-Anhalt, Germany, 39120